--22. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles are present in said gel at a concentration of from 50 to 300 g/l.

--23. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles are present in said gel at a concentration of from 60 to 200 g/l.

--24. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles have a mean diameter of from 5 to 150 micrometers.

--25. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles have a mean diameter of from 20 to 80 micrometers.

--26. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles are bioresorbable within a period of 1 year to 3 years.

--27. (New) The injectable implant for human administration, according to claim 21, wherein said microspheres or microparticles consists of a polymer consisting of the group poly-L-lactic acid, poly-D-lactic acid and mixtures thereof.

--28. (New) The injectable implant for human administration, according to claim 21, wherein said polylactic acid has a molecular mass of between 70,000 and 175,000 Dalton.

--29. (New) The injectable implant for human administration, according to claim 21, wherein said polylactic acid has a molecular mass of between 120,000 and 170,000 Dalton.

--30. (New) The injectable implant for human administration, according to claim 21, wherein said polylactic acid has an intrinsic viscosity of between 3 and 4 dl/g.

--31. (New) The injectable implant for human administration, according to claim 21, wherein said polylactic acid has an intrinsic viscosity of between 3.35 and 3.65 dl/g.

--32. (New) The injectable implant for human administration, according to claim 21, wherein said polylactic acid has a percentage of residual monomer < 0.1%.

--33. The injectable implant for human administration, according to claim 21, wherein said polylactic acid has a percentage of residual solvents< 0.01%.

--34. (New) The injectable implant for human administration, according to claim 21, wherein said gel comprises a gelling agent consisting essentially of carboxymethylcellulose (CMC) or hydroxypropylmethylcellulose (HPMC) at a concentration by weight of 0.1 to 7.5%.

--35. (New) The injectable implant for human administration, according to claim 21, wherein said gel comprises a gelling agent consisting essentially of carboxymethylcellulose (CMC) or hydroxypropylmethylcellulose (HPMC) at a concentration by weight of 0.1 to 5.0%.

--36. (New) The product obtained by freeze-drying the injectable implant for human administration, according to claim 21, wherein said product is capable of reconstituting an injectable implant for human administration upon addition of water for injection.--